NZ510434A - Heterocylic substituted quinazoline derivatives useful as VEGF inhibitors - Google Patents

Heterocylic substituted quinazoline derivatives useful as VEGF inhibitors

Info

Publication number
NZ510434A
NZ510434A NZ510434A NZ51043499A NZ510434A NZ 510434 A NZ510434 A NZ 510434A NZ 510434 A NZ510434 A NZ 510434A NZ 51043499 A NZ51043499 A NZ 51043499A NZ 510434 A NZ510434 A NZ 510434A
Authority
NZ
New Zealand
Prior art keywords
methoxy
alkyl
ethoxy
group
compound
Prior art date
Application number
NZ510434A
Other languages
English (en)
Inventor
Laurent Francois And Hennequin
Georges Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ510434A publication Critical patent/NZ510434A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seal Device For Vehicle (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ510434A 1998-10-08 1999-10-05 Heterocylic substituted quinazoline derivatives useful as VEGF inhibitors NZ510434A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98402496 1998-10-08
PCT/GB1999/003295 WO2000021955A1 (en) 1998-10-08 1999-10-05 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
NZ510434A true NZ510434A (en) 2003-10-31

Family

ID=8235527

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510434A NZ510434A (en) 1998-10-08 1999-10-05 Heterocylic substituted quinazoline derivatives useful as VEGF inhibitors

Country Status (19)

Country Link
US (1) US7262201B1 (enExample)
EP (1) EP1119567B1 (enExample)
JP (2) JP2002527436A (enExample)
KR (1) KR100860295B1 (enExample)
CN (1) CN1161352C (enExample)
AT (1) ATE294796T1 (enExample)
AU (1) AU756556B2 (enExample)
BR (1) BR9914326A (enExample)
CA (1) CA2344290C (enExample)
DE (1) DE69925141T2 (enExample)
DK (1) DK1119567T3 (enExample)
ES (1) ES2241324T3 (enExample)
HK (1) HK1039126B (enExample)
IL (2) IL142359A0 (enExample)
NO (1) NO322644B1 (enExample)
NZ (1) NZ510434A (enExample)
PT (1) PT1119567E (enExample)
WO (1) WO2000021955A1 (enExample)
ZA (1) ZA200102655B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3522727B2 (ja) 1999-11-05 2004-04-26 アストラゼネカ アクチボラグ Ｖｅｇｆ阻害剤としてのキナゾリン誘導体
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
DE60121931T2 (de) 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301120A2 (hu) 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
EE200200715A (et) * 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
BR0113358A (pt) 2000-08-21 2003-07-01 Astrazeneca Ab Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI1318997T1 (sl) 2000-09-15 2006-12-31 Vertex Pharma Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
DK1343782T3 (da) 2000-12-21 2009-08-24 Smithkline Beecham Corp Pyrimidinaminer som angiogenesemodulatorer
AP2003002825A0 (en) * 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
RU2332415C2 (ru) * 2001-04-27 2008-08-27 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, полезные в качестве ингибиторов протеинкиназы
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
ATE339419T1 (de) 2002-08-02 2006-10-15 Vertex Pharma Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
NZ539408A (en) * 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
GB0318423D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
CA2542076C (en) 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US8153643B2 (en) * 2004-10-12 2012-04-10 Astrazeneca Ab Quinazoline derivatives
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
EP1928456B1 (en) 2005-09-30 2015-04-22 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US7528142B2 (en) 2005-11-03 2009-05-05 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
WO2008137619A2 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
PT2947072T (pt) 2008-03-17 2016-12-06 Ambit Biosciences Corp 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
MX2011002312A (es) 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2763987B1 (en) 2011-10-06 2018-07-18 Bayer CropScience AG Heterocyclylpyri(mi)dinylpyrazole as fungicidals
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
PT3311845T (pt) 2013-09-16 2020-04-02 Astrazeneca Ab Nanopartículas poliméricas terapêuticas e métodos para fabrico e uso das mesmas
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9771333B2 (en) 2013-11-20 2017-09-26 Signalchem Lifesciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
CN113549053B (zh) * 2020-04-23 2022-09-13 沈阳中化农药化工研发有限公司 一种吡唑喹（唑）啉醚类化合物及其应用
EP4201936A4 (en) * 2020-08-20 2024-02-21 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. HETEROAROMATIC RING COMPOUND AS A RET KINASE INHIBITOR AND PRODUCTION AND USE THEREOF

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
IL101291A0 (en) 1991-03-22 1992-11-15 Nippon Soda Co 2-pyridine derivatives,their preparation and their use as fungicides
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH10508486A (ja) 1994-11-07 1998-08-25 メルク エンド カンパニー インコーポレーテッド 修飾神経ペプチドｙレセプター
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
TW334434B (en) 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
WO1998014431A1 (en) 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
WO1998002434A1 (en) * 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents

Also Published As

Publication number Publication date
NO20011739L (no) 2001-06-07
IL142359A (en) 2008-11-03
DK1119567T3 (da) 2005-07-25
AU756556B2 (en) 2003-01-16
AU6112899A (en) 2000-05-01
CN1322202A (zh) 2001-11-14
US7262201B1 (en) 2007-08-28
JP2002527436A (ja) 2002-08-27
BR9914326A (pt) 2001-06-26
KR20010085890A (ko) 2001-09-07
JP2011126888A (ja) 2011-06-30
CA2344290C (en) 2009-06-02
WO2000021955A1 (en) 2000-04-20
NO322644B1 (no) 2006-11-13
HK1039126A1 (en) 2002-04-12
IL142359A0 (en) 2002-03-10
PT1119567E (pt) 2005-08-31
DE69925141D1 (de) 2005-06-09
ES2241324T3 (es) 2005-10-16
DE69925141T2 (de) 2006-04-27
NO20011739D0 (no) 2001-04-06
ATE294796T1 (de) 2005-05-15
ZA200102655B (en) 2002-09-30
CA2344290A1 (en) 2000-04-20
HK1039126B (en) 2005-09-30
KR100860295B1 (ko) 2008-09-25
CN1161352C (zh) 2004-08-11
EP1119567A1 (en) 2001-08-01
EP1119567B1 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
EP1119567B1 (en) Quinazoline derivatives
EP1005470B1 (en) Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1154774B1 (en) Quinazoline derivatives as angiogenesis inhibitors
US20030199491A1 (en) Quinoline derivatives having vegf inhibiting activity
NZ523388A (en) Cinnoline compounds
EP0912557A1 (en) Oxindole derivatives
NZ523987A (en) Indole, azaindole and indazole derivatives having VEGF inhibiting activity
AU2001276521A1 (en) Cinnoline compounds
MXPA01003468A (en) Quinazoline derivatives

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired